{
    "clinical_study": {
        "@rank": "153018", 
        "arm_group": [
            {
                "arm_group_label": "New Eye Drop Formulation", 
                "arm_group_type": "Experimental", 
                "description": "1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation in each eye  as per protocol for 90 days."
            }, 
            {
                "arm_group_label": "REFRESH PLUS\u00ae", 
                "arm_group_type": "Active Comparator", 
                "description": "1 to 2 drops carboxymethylcellulose sodium based (REFRESH PLUS\u00ae) eye drops in each eye as per protocol for 90 days."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will compare the safety and efficacy of a new eye drop formulation with REFRESH\n      PLUS\u00ae in participants following LASIK surgery."
        }, 
        "brief_title": "A Study to Compare the Safety and Efficacy of a New Eye Drop Formulation With REFRESH PLUS\u00ae in Participants Following LASIK Refractive Surgery", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Bilateral LASIK Surgery", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        -Patients scheduled for LASIK surgery in both eyes.\n\n        Exclusion Criteria:\n\n          -  Any systemic medication use within 3 months of screening (including over the counter,\n             herbal, prescription, or nutritional supplement) which may affect dry eye or vision\n\n          -  Use of topical eye medication other than prescribed for use in pre- or post-operative\n             care\n\n          -  Use of RESTASIS\u00ae or other topical ophthalmic cyclosporine product within 6 months\n             prior to Screening\n\n          -  Eye infection, inflammation, or allergy\n\n          -  Soft contact lenses in the previous 7 days or rigid contact lenses in the previous 30\n             days prior to LASIK surgery."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "214", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01886690", 
            "org_study_id": "11002X-002"
        }, 
        "intervention": [
            {
                "arm_group_label": "New Eye Drop Formulation", 
                "description": "1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation in each eye  as per protocol for 90 days.", 
                "intervention_name": "carboxymethylcellulose sodium based new eye drop formulation", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "REFRESH PLUS\u00ae", 
                "description": "1 to 2 drops carboxymethylcellulose sodium based (REFRESH PLUS\u00ae) eye drops in each eye as per protocol for 90 days.", 
                "intervention_name": "carboxymethylcellulose sodium based eye drops", 
                "intervention_type": "Drug", 
                "other_name": "REFRESH PLUS\u00ae"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Tetrahydrozoline", 
                "Carboxymethylcellulose Sodium"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 13, 2014", 
        "link": {
            "description": "More Information", 
            "url": "http://www.allerganclinicaltrials.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "New South Wales", 
                        "country": "Australia"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kelowna", 
                        "country": "Canada", 
                        "state": "British Columbia"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Australia", 
                "Canada"
            ]
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "clinicaltrials@allergan.com", 
            "last_name": "Allergan Inc."
        }, 
        "overall_official": {
            "affiliation": "Allergan", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Ocular Surface Disease Index\u00a9 (OSDI) Score using a 5-Point Scale", 
            "safety_issue": "No", 
            "time_frame": "Day 90"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01886690"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Corneal Staining", 
                "safety_issue": "No", 
                "time_frame": "Day 90"
            }, 
            {
                "measure": "Tear Break-up Time (TBUT)", 
                "safety_issue": "No", 
                "time_frame": "Day 90"
            }, 
            {
                "measure": "Schirmer Test", 
                "safety_issue": "No", 
                "time_frame": "Day 90"
            }, 
            {
                "measure": "Uncorrected Visual Acuity", 
                "safety_issue": "No", 
                "time_frame": "Day 90"
            }
        ], 
        "source": "Allergan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}